Skip to content
WhatsApp5544 1314

PATENTED INGREDIENT

UTHEVER® NMN (β-Nicotinamide Mononucleotide, >99.8% Purity, Human Clinical Trial NCT04228640)

UTHEVER® NMN is a branded ingredient in the ACC Biotech portfolio, developed and manufactured by EffePharm Ltd. (Shanghai, China), with purity above 99.8% and a completed multicentre, randomised, double-blind, placebo-controlled human clinical trial (NCT04228640). This page summarises the ingredient information currently on file and how to request more.

Contact usBack to the library
UTHEVER® NMN (β-Nicotinamide Mononucleotide, >99.8% Purity, Human Clinical Trial NCT04228640)

INGREDIENT PROFILE

What this ingredient is documented for

Origin
China
Developer
EffePharm Ltd. (Songjiang District, Shanghai, China; office in North Point, Hong Kong)
  • UTHEVER® is EffePharm's trademarked NMN (β-nicotinamide mononucleotide) ingredient brand, CAS No. 1094-61-7; the brand states it was the No.1 trademarked NMN ingredient by B2B sales volume in the USA in 2024
  • Purity above 99.8%, produced in ISO 9001 and cGMP facilities; G3 ultra-high-density grade with a granule density of approximately 0.6–0.8 g/ml, suited to high-dose tableting and capsule filling
  • Holds a US FDA New Dietary Ingredient (NDI) letter of no objection, with Halal and Kosher certification; NPA (Natural Products Association) member ingredient
  • Backed by a multicentre, randomised, double-blind, placebo-controlled human clinical trial (NCT04228640, published 2022 in Frontiers in Aging): 66 healthy subjects aged 40–65, 300 mg/day for 60 days
  • Trial outcomes: NAD+/NADH up 38% from baseline (placebo 14.3%), six-minute walking endurance up 6.5% (placebo 3.9%), SF-36 quality-of-life score up 6.5% (placebo 3.4%); no significant changes in liver/kidney function or blood pressure
  • Supplied as raw powder, sublingual powder, tablets, capsules and sachets, with controlled- and sustained-release options; UthPeak™ reduced NMN (NMNH) is also available from the same group

QUICK REFERENCE

Key ingredient facts

Country of origin
China
Developer
EffePharm Ltd.
Purity
>99.8%
CAS No.
1094-61-7
Human clinical trial
NCT04228640

About UTHEVER® NMN (β-Nicotinamide Mononucleotide, >99.8% Purity, Human Clinical Trial NCT04228640)

UTHEVER® NMN is a branded ingredient in the ACC Biotech portfolio, developed and manufactured by EffePharm Ltd. (Songjiang District, Shanghai, China), with China listed as the country of origin. UTHEVER® was the first NMN (β-nicotinamide mononucleotide) ingredient brand to complete a large-scale human clinical trial. CAS No. 1094-61-7.

Specification and manufacturing: purity above 99.8%, produced in ISO 9001 and cGMP facilities. The G3 ultra-high-density grade has a granule density of approximately 0.6–0.8 g/ml, suited to high-dose tableting, capsules and sachets. Sublingual powder, controlled- and sustained-release formats and UTHEVER® cosmetic-grade applications are also available.

Regulatory and certification: a US FDA New Dietary Ingredient (NDI) letter of no objection has been received, alongside Halal and Kosher certification, and the ingredient is an NPA (Natural Products Association) member ingredient.

Human clinical trial (NCT04228640, published 2022 in Frontiers in Aging): a multicentre, randomised, double-blind, placebo-controlled design in which 66 healthy subjects aged 40–65 took 300 mg per day for 60 days. NAD+/NADH rose 38% from baseline (placebo 14.3%), six-minute walking endurance improved 6.5% (placebo 3.9%) and SF-36 quality-of-life scores improved 6.5% (placebo 3.4%), with no significant changes in liver or kidney function or blood pressure.

This page summarises the ingredient information currently on file and how to request more. For formulation advice, specification sheets, certificates of analysis or pricing, please contact ACC Biotech.

Frequently asked questions

These answers summarise only the catalogue information ACC Biotech holds today and how to get in touch.

What is the purity and specification of UTHEVER® NMN?

Purity is above 99.8%, CAS No. 1094-61-7, produced in ISO 9001 and cGMP facilities; the G3 grade has a granule density of approximately 0.6–0.8 g/ml. Full specification sheets are available from ACC Biotech.

Is there human clinical data for UTHEVER® NMN?

Yes. A multicentre, randomised, double-blind, placebo-controlled trial (NCT04228640) using 300 mg/day for 60 days reported a 38% rise in NAD+/NADH from baseline and 6.5% improvements in both six-minute walking endurance and SF-36 quality-of-life scores.

Which regulatory documents and certifications are available?

A US FDA New Dietary Ingredient (NDI) letter of no objection, plus Halal and Kosher certification. Ask ACC Biotech for the current document list.

How do I request formulation, documentation or purchasing information?

Contact ACC Biotech with your dosage form, target market and the documents you need, and the team will follow up.

MORE INGREDIENTS

FORMULATION

Discuss this ingredient with ACC

Bring this ingredient into a formula, documentation and sourcing conversation with the ACC team.

Contact usBack to the library